title: Negative regulation of interferon-β gene expression during acute and persistent virus infections.
abstract: The production of type I interferons (IFNs) in response to viral infections is critical for antiviral immunity. However, IFN production is transient, and continued expression can lead to inflammatory or autoimmune diseases. Thus, understanding the mechanisms underlying the negative regulation of IFN expression could lead to the development of novel therapeutic approaches to the treatment of these diseases. We report that the transcription factor IRF3 plays a central role in the negative regulation of interferon-β (IFNβ) expression during both acute and persistent (chronic) virus infections. We show that the degradation of IRF3 during acute infections, rather than the activation of transcriptional repressors, leads to the down regulation of IFNβ expression. We also show that the block to IFNβ expression in mouse embryonic fibroblasts that are persistently infected with Sendai virus (SeV) correlates with the absence of transcriptionally active IRF3. Remarkably, ongoing protein synthesis and viral replication are required to maintain repression of the IFNβ gene in persistently infected cells, as the gene can be activated by the protein synthesis inhibitor cycloheximide, or by the antiviral drug ribavirin. Finally, we show that the SeV V protein inhibits IRF3 activity in persistently infected cells. Thus, in conjunction with the known interference with STAT1 by the SeV C protein, both IFN activation and its signaling pathways are blocked in persistently infected cells. We conclude that the transcription factor IRF3 is targeted for turnover and inactivation through distinct mechanisms from both the host cells and virus, leading to the inhibition of IFNβ gene expression during acute and persistent viral infections. These observations show that IRF3 plays a critical role, not only in the activation of the IFNβ gene, but also in the controlling the duration of its expression. (284 words).
authors.affiliation: Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts, United States of America.
authors.forename: Junqiang
authors.initials: J
authors.lastname: Ye
authors.forename: Tom
authors.initials: T
authors.lastname: Maniatis
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000276:immunology* / Q000821:virology*; D002460:Cell Line; D003513:Cycloheximide / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000502:physiology / Q000821:virology; D005786:Gene Expression Regulation; D006801:Humans; D007113:Immunity, Innate; D007249:Inflammation / Q000276:immunology* / Q000821:virology*; D050838:Interferon Regulatory Factor-3 / Q000235:genetics / Q000378:metabolism; D016899:Interferon-beta / Q000235:genetics* / Q000276:immunology; D051379:Mice; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D010253:Respirovirus Infections / Q000188:drug therapy / Q000378:metabolism; D012254:Ribavirin / Q000494:pharmacology / Q000627:therapeutic use; D029082:Sendai virus / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D014764:Viral Proteins / Q000378:metabolism; D014777:Virus Diseases / Q000235:genetics / Q000276:immunology*
chemical_list: D000998:Antiviral Agents; D050838:Interferon Regulatory Factor-3; C494233:Irf3 protein, mouse; D011500:Protein Synthesis Inhibitors; C111739:V protein, Sendai virus; D014764:Viral Proteins; D012254:Ribavirin; D016899:Interferon-beta; D003513:Cycloheximide